Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences 3D-Bioprinting "Track B"

William G Whitford's Biography



William G Whitford, Strategic Solutions Leader Bioprocess, GE Healthcare Life Sciences

Bill Whitford is Strategic Solutions Leader, BioProcess, GE Healthcare in Logan, UT with over 20 years’ experience in biotechnology product and process development. He joined the company 16 years ago as a team leader in R&D developing products supporting biomass expansion, protein expression and virus secretion in mammalian and invertebrate cell lines. Products he has commercialized include defined and animal product-free hybridoma media, fed-batch supplements, and aqueous lipid dispersions. An invited lecturer at international conferences, Bill has published over 250 articles, book chapters and patents in several areas of bioproduction. He now enjoys such industry activities as serving on the editorial advisory board for BioProcess International.

William G Whitford Image

Digital Biomanufacturing Tools Support Creating 3D Tissue-Like Structures

Friday, 5 October 2018 at 10:00

Add to Calendar ▼2018-10-05 10:00:002018-10-05 11:00:00Europe/LondonDigital Biomanufacturing Tools Support Creating 3D Tissue-Like StructuresSELECTBIOenquiries@selectbiosciences.com

Digital biomanufacturing refers to such concepts as increased monitoring, control algorithms, machine-learning and process modeling to a new level of process understanding, prediction and control in biotechnology. The IIoT, Big Data and Cloud technologies insure that (historical and real-time) data being collected can be employed productively in richer data management, analysis and model generation. Digital biomanufacturing will assist in the modeling and imaging required to recapitulate the (often personalized) complex and heterogeneous architecture of functional tissues and organs. It will also provide the required coordination and dynamic control of consequent complex tomographic information and models, multimode 3D printing and biofabrication processes, as well as such ancillary procedures as the environmental control of bioinks and nascent constructs. New and even commercially available approaches exist for the processing eg, medical imaging and the results of previous run records. They can generate printing formulas, recipes and fabrication scenarios considering matrix polymerization and integrity constraints. Monitoring and control goals include the printing environment, cell viability and adhesion and matrix assessment. These newer and more powerful algorithms support multi-material and multi-mode bioprinting and can consider the effects of intra-construct gradients and distinctions. Finally, they will assure compliance and reporting to, internal QC, QA and Regulatory.


Add to Calendar ▼2018-10-04 00:00:002018-10-05 00:00:00Europe/London3D-Bioprinting "Track B"SELECTBIOenquiries@selectbiosciences.com